cyproterone acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antiandrogens | 766 | 427-51-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An agent with anti-androgen and progestational properties. It shows competitive binding with dihydrotestosterone at androgen receptor sites.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.10 | g | O |
| 0.10 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.00 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 1 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 10.28 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1974 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Meningioma | 921.82 | 56.09 | 126 | 442 | 3759 | 63484695 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Meningioma | 397.49 | 46.99 | 58 | 520 | 1378 | 34954975 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Meningioma | 1213.72 | 39.42 | 173 | 975 | 4125 | 79739115 |
| Prosopagnosia | 48.82 | 39.42 | 6 | 1142 | 39 | 79743201 |
| Hepatitis fulminant | 45.08 | 39.42 | 12 | 1136 | 7250 | 79735990 |
| Frontotemporal dementia | 39.74 | 39.42 | 7 | 1141 | 608 | 79742632 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G03HA01 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ANTIANDROGENS Antiandrogens, plain |
| ATC | G03HB01 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ANTIANDROGENS Antiandrogens and estrogens |
| MeSH PA | D000726 | Androgen Antagonists |
| MeSH PA | D006727 | Hormone Antagonists |
| CHEBI has role | CHEBI:35497 | antiandrogen |
| CHEBI has role | CHEBI:59826 | progestins |
| CHEBI has role | CHEBI:176497 | geroprotectors |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D003270 | Contraceptive Agents |
| MeSH PA | D003272 | Contraceptive Agents, Male |
| MeSH PA | D012102 | Reproductive Control Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Androgen receptor | Nuclear hormone receptor | ANTAGONIST | IC50 | 7.43 | WOMBAT-PK | IUPHAR | |||
| Glucocorticoid receptor | Nuclear hormone receptor | IC50 | 7.80 | WOMBAT-PK | |||||
| Mu-type opioid receptor | GPCR | Ki | 6.05 | DRUG MATRIX | |||||
| Progesterone receptor | Nuclear hormone receptor | IC50 | 9.68 | WOMBAT-PK | |||||
| Androgen receptor | Transcription factor | IC50 | 4.74 | CHEMBL | |||||
| Progesterone receptor | Transcription factor | Ki | 8.32 | DRUG MATRIX | |||||
| Adenosine receptor A1 | GPCR | IC50 | 8.30 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| N0000167457 | NUI |
| D01368 | KEGG_DRUG |
| 22054 | RXNORM |
| C0056855 | UMLSCUI |
| CHEBI:50743 | CHEBI |
| CHEBI:50742 | CHEBI |
| CA4 | PDB_CHEM_ID |
| CHEMBL139835 | ChEMBL_ID |
| D017373 | MESH_DESCRIPTOR_UI |
| DB04839 | DRUGBANK_ID |
| 9880 | PUBCHEM_CID |
| 2865 | IUPHAR_LIGAND_ID |
| 4KM2BN5JHF | UNII |
| 003475 | NDDF |
| 004825 | NDDF |
| 126119006 | SNOMEDCT_US |
| 126120000 | SNOMEDCT_US |
| 96370002 | SNOMEDCT_US |
| C0010621 | UMLSCUI |
| 2050 | INN_ID |
| 2098-66-0 | SECONDARY_CAS_RN |
| 5284537 | PUBCHEM_CID |
| D003534 | MESH_DESCRIPTOR_UI |
| E61Q31EK2F | UNII |
Pharmaceutical products:
None